Rxivist logo

In silico identification and validation of inhibitors of the interaction between neuropilin receptor 1 and SARS-CoV-2 Spike protein

By Samantha Perez-Miller, Marcel Patek, Aubin Moutal, Carly R. Cabel, Curtis A. Thorne, Samuel K. Campos, Rajesh Khanna

Posted 23 Sep 2020
bioRxiv DOI: 10.1101/2020.09.22.308783

Neuropilin-1 (NRP-1) is a multifunctional transmembrane receptor for ligands that affect developmental axonal growth and angiogenesis. In addition to a role in cancer, NRP-1 is a reported entry point for several viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19). The furin cleavage product of SARS-CoV-2 Spike protein takes advantage of the vascular endothelial growth factor A (VEGF-A) binding site on NRP-1 which accommodates a polybasic stretch ending in a C-terminal arginine. This site has long been a focus of drug discovery efforts for cancer therapeutics. We recently showed that interruption of the VEGF-A/NRP-1 signaling pathway ameliorates neuropathic pain and hypothesize that interference of this pathway by SARS-CoV-2 spike protein interferes with pain signaling. Here, we report hits from a small molecule and natural product screen of nearly 0.5 million compounds targeting the VEGF-A binding site on NRP-1. We identified nine chemical series with lead- or drug-like physico-chemical properties. Using an ELISA, we demonstrate that six compounds disrupt VEGF-A-NRP-1 binding more effectively than EG00229, a known NRP-1 inhibitor. Secondary validation in cells revealed that almost all tested compounds inhibited VEGF-A triggered VEGFR2 phosphorylation. Two compounds displayed robust inhibition of a recombinant vesicular stomatitis virus protein that utilizes the SARS-CoV-2 Spike for entry and fusion. These compounds represent a first step in a renewed effort to develop small molecule inhibitors of the VEGF-A/NRP-1 signaling for the treatment of neuropathic pain and cancer with the added potential of inhibiting SARS-CoV-2 virus entry. ### Competing Interest Statement R. Khanna is the co-founder of Regulonix LLC, a company developing non-opioids drugs for chronic pain. In addition, R. Khanna has patents US10287334 and US10441586 issued to Regulonix LLC. The other authors declare no competing financial interests. * ACE-2 : angiotensin converting enzyme-2 ADME : absorption, distribution, metabolism, and excretion BBB : blood brain barrier CNS : central nervous system COCONUT : COlleCtion of Open NatUral producTs COVID-19 : coronavirus disease 2019 ELISA : enzyme linked immunosorbent assay NC : natural compound NRP-1 : Neuropilin 1 PDB : protein data bank Ro5 : Lipinski rule of 5 SARS-CoV-2 : severe acute respiratory syndrome coronavirus 2 VEGF-A : vascular endothelial growth factor-A VSV : vesicular stomatitis virus

Download data

  • Downloaded 749 times
  • Download rankings, all-time:
    • Site-wide: 28,038
    • In neuroscience: 3,896
  • Year to date:
    • Site-wide: 4,093
  • Since beginning of last month:
    • Site-wide: 7,402

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)